Orbimed Advisors LLC Aerie Pharmaceuticals Inc Transaction History

Orbimed Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$28.97 - $48.21 $1.68 Million - $2.8 Million	-58,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$36.32 - $49.25 $29.6 Million - $40.1 Million	-814,100 Reduced 93.35%	58,000 $2.76 Million
Q4 2018 Feb 14, 2019	SELL	$33.0 - $60.04 $11.5 Million - $20.9 Million	-347,730 Reduced 28.51%	872,100 $31.5 Million
Q3 2018 Nov 14, 2018	SELL	$56.15 - $73.9 $37.3 Million - $49.1 Million	-664,270 Reduced 35.26%	1,219,830 $75.1 Million
Q1 2018 May 15, 2018	BUY	$51.15 - $61.0 $28.4 Million - $33.8 Million	554,500 Added 41.7%	1,884,100 $102 Million
Q4 2017 Feb 14, 2018	SELL	$50.85 - $65.1 $5.52 Million - $7.07 Million	-108,582 Reduced 7.55%	1,329,600 $79.4 Million
Q3 2017 Nov 14, 2017	BUY	$48.6 - $60.1 $69.9 Million - $86.4 Million	1,438,182	1,438,182 $69.9 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.